Special Issue "RNA Therapeutics: From Concepts to Applications"

A special issue of Non-Coding RNA (ISSN 2311-553X).

Deadline for manuscript submissions: closed (31 October 2021).

Special Issue Editor

Prof. Dr. André P. Gerber
E-Mail Website
Guest Editor
Department of Microbial Sciences, School of Biosciences and Medicine, Faculty of Health and Medical Sciences, University of Surrey, Stag Hill Campus 19AX01, Guildford GU2 7XH, UK
Interests: posttranscriptional gene regulation; RNA-binding proteins; non-coding RNA; translational control; ribonomics
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

RNA has moved into the spotlight as a promising target and effector for therapeutic intervention. While a variety of RNA-targeting approaches have already been developed and evaluated, recent breakthroughs with small non-coding RNAs and RNA-based vaccines showcase the great potential and nurture further development and expansion of RNA therapeutic approaches.

For this Special Issue, we welcome the contribution of research or review manuscripts in the broad area of RNA therapeutics. This could cover (i) the development, testing, and delivery of small antisense oligonucleotides and/or antagomirs for gene expression modulation and correction; (ii) the screening, validation, delivery and efficacy testing of small molecules/drugs that interfere with or consolidate RNA-RNA or RNA-protein interactions; (iii) the implementation of long ncRNA (lncRNA) and mRNA for therapeutics; and (iv) recent progress in the delivery of RNAs to particular cells/tissues. Critical reviews that highlight the advantages and disadvantages of RNA therapeutic approaches, including provocative statements and opinions on future developments are also particularly welcome.

Essentially, this Special Issue shall provide a broad perspective of current approaches and future developments in RNA therapeutics, with an emphasis on ncRNAs as a target or drug for therapeutic intervention and eventual curation of human disease.

Prof. Dr. André P. Gerber
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Non-Coding RNA is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Gene therapy
  • ncRNA
  • antisense oligonucleotides
  • small molecules
  • drug development
  • RNA-RNA interactions
  • RNA-protein interactions
  • RNA processing
  • human disease

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Article
LncRNA TP53TG1 Promotes the Growth and Migration of Hepatocellular Carcinoma Cells via Activation of ERK Signaling
Non-Coding RNA 2021, 7(3), 52; https://0-doi-org.brum.beds.ac.uk/10.3390/ncrna7030052 - 28 Aug 2021
Viewed by 1118
Abstract
Long non-coding RNA (lncRNA) TP53 target 1 (TP53TG1) was discovered as a TP53 target gene. TP53TG1 has been reported as having dual roles by exerting tumor-suppressive and oncogenic activities that vary depending on the cancer type. Yet, the role of TP53TG1 in hepatocellular [...] Read more.
Long non-coding RNA (lncRNA) TP53 target 1 (TP53TG1) was discovered as a TP53 target gene. TP53TG1 has been reported as having dual roles by exerting tumor-suppressive and oncogenic activities that vary depending on the cancer type. Yet, the role of TP53TG1 in hepatocellular carcinoma (HCC) is not fully understood. In this study, we performed both gain- and loss-of-function studies to determine the biological role of TP53TG1 in HCC. We found that the knockdown of TP53 in HCC cells caused the upregulation of TP53TG1. Furthermore, we found that the knockdown of TP53TG1 not only suppressed HCC cell proliferation and migration, but also reduced intrinsic ERK signaling. In contrast, the overexpression of TP53TG1 increased ERK activation and enhanced HCC proliferation. In conclusion, our study reveals an oncogenic role of TP53TG1 in HCC, which provides a novel insight into the cell-type-specific function of TP53TG1 in HCC. Full article
(This article belongs to the Special Issue RNA Therapeutics: From Concepts to Applications)
Show Figures

Figure 1

Article
MicroRNAs and Long Non-Coding RNAs as Potential Candidates to Target Specific Motifs of SARS-CoV-2
Non-Coding RNA 2021, 7(1), 14; https://0-doi-org.brum.beds.ac.uk/10.3390/ncrna7010014 - 18 Feb 2021
Cited by 8 | Viewed by 3498
Abstract
The respiratory system is one of the most affected targets of SARS-CoV-2. Various therapies have been utilized to counter viral-induced inflammatory complications, with diverse success rates. Pending the distribution of an effective vaccine to the whole population and the achievement of “herd immunity”, [...] Read more.
The respiratory system is one of the most affected targets of SARS-CoV-2. Various therapies have been utilized to counter viral-induced inflammatory complications, with diverse success rates. Pending the distribution of an effective vaccine to the whole population and the achievement of “herd immunity”, the discovery of novel specific therapies is to be considered a very important objective. Here, we report a computational study demonstrating the existence of target motifs in the SARS-CoV-2 genome suitable for specific binding with endogenous human micro and long non-coding RNAs (miRNAs and lncRNAs, respectively), which can, therefore, be considered a conceptual background for the development of miRNA-based drugs against COVID-19. The SARS-CoV-2 genome contains three motifs in the 5′UTR leader sequence recognized by selective nucleotides within the seed sequence of specific human miRNAs. The seed of 57 microRNAs contained a “GGG” motif that promoted leader sequence-recognition, primarily through offset-6mer sites able to promote microRNAs noncanonical binding to viral RNA. Similarly, lncRNA H19 binds to the 5′UTR of the viral genome and, more specifically, to the transcript of the viral gene Spike, which has a pivotal role in viral infection. Notably, some of the non-coding RNAs identified in our study as candidates for inhibiting SARS-CoV-2 gene expression have already been proposed against diverse viral infections, pulmonary arterial hypertension, and related diseases. Full article
(This article belongs to the Special Issue RNA Therapeutics: From Concepts to Applications)
Show Figures

Graphical abstract

Back to TopTop